BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34745002)

  • 1. The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.
    Xi Z; Jones PS; Mikamoto M; Jiang X; Faje AT; Nie C; Labelle KE; Zhou Y; Miller KK; Soberman RJ; Zhang X
    Front Endocrinol (Lausanne); 2021; 12():726448. PubMed ID: 34745002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
    Mei Y; Bi WL; Greenwald NF; Du Z; Agar NY; Kaiser UB; Woodmansee WW; Reardon DA; Freeman GJ; Fecci PE; Laws ER; Santagata S; Dunn GP; Dunn IF
    Oncotarget; 2016 Nov; 7(47):76565-76576. PubMed ID: 27655724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas.
    Zhou W; Zhang C; Zhang D; Peng J; Ma S; Wang X; Guan X; Li P; Li D; Jia G; Jia W
    J Neurooncol; 2020 Sep; 149(3):473-487. PubMed ID: 33034841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
    Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The identification of human pituitary adenoma-initiating cells.
    Manoranjan B; Mahendram S; Almenawer SA; Venugopal C; McFarlane N; Hallett R; Vijayakumar T; Algird A; Murty NK; Sommer DD; Provias JP; Reddy K; Singh SK
    Acta Neuropathol Commun; 2016 Nov; 4(1):125. PubMed ID: 27894339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression profile of PD-L1 and CD8
    Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX
    J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior.
    Righi A; Morandi L; Leonardi E; Farnedi A; Marucci G; Sisto A; Frank G; Faustini-Fustini M; Zoli M; Mazzatenta D; Agati R; Foschini MP
    Hum Pathol; 2013 Nov; 44(11):2400-9. PubMed ID: 24007691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
    Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary adenoma: a DNA flow cytometric study of 192 clinicopathologically characterized tumors.
    Gaffey TA; Scheithauer BW; Leech RW; Blick K; Kovacs K; Horvath E; Weaver AL; Lloyd RV; Ebersold M; Laws ER; DeBault LE
    Clin Neuropathol; 2005; 24(2):56-63. PubMed ID: 15803804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Relationship Between Phospho-p38, Matrix Metalloproteinase 9, and Major Histocompatibility Complex Class I Chain-Related Molecule A Expression in Pituitary Adenomas Demonstrates a New Mechanism of Pituitary Adenoma Immune Escape.
    Han X; Geng X; Li Z; Chen Z; Liu Y; Liu P; Wang Q; Li C; Ai D; Li Z
    World Neurosurg; 2019 Mar; 123():e116-e124. PubMed ID: 30458325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
    Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
    J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between NF-κB, MMP-9, and MICA expression in pituitary adenomas reveals a new mechanism of pituitary adenomas immune escape.
    Chen Z; Li Z; Chang Y; Ma L; Xu W; Li M; Li J; Zhang W; Sun Q; An X; Li Z
    Neurosci Lett; 2015 Jun; 597():77-83. PubMed ID: 25921632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
    Suteau V; Collin A; Menei P; Rodien P; Rousselet MC; Briet C
    Cancer Immunol Immunother; 2020 Oct; 69(10):2053-2061. PubMed ID: 32445029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.
    Wu Y; Bai J; Li Z; Wang F; Cao L; Liu C; Yu S; Yu G; Zhang Y
    Pituitary; 2015 Jun; 18(3):335-42. PubMed ID: 24917361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
    Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrences of Pituitary Adenomas or Second De Novo Tumors: Comparisons with First Tumors.
    Saeger W; Müller M; Buslei R; Flitsch J; Fahlbusch R; Buchfelder M; Knappe UJ; Crock PA; Lüdecke DK
    World Neurosurg; 2018 Nov; 119():e118-e124. PubMed ID: 30026158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
    Matsuyama J
    Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.
    Feng J; Hong L; Wu Y; Li C; Wan H; Li G; Sun Y; Yu S; Chittiboina P; Montgomery B; Zhuang Z; Zhang Y
    J Neurooncol; 2014 Sep; 119(2):307-15. PubMed ID: 24916845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.